Cardiovascular Therapeutics

PI3K Inhibitors in Cardiovascular Disease (Review Article)
Andreas Eisenreich, Ursula Rauch

Cardiac Cell Therapies: The Next Generation (Review Article)
Yeong-Hoon Choi, Tomo Saric, Boris Nasseri, Stefan Hühn, et al

Nutraceuticals and Atherosclerosis: Human Trials
Lina Badimon, Gemma Vilahur, Teresa Padro

Atorvastatin Decreases C-Reactive Protein-Induced Inflammatory Response in Pulmonary Artery Smooth Muscle Cells by Inhibiting Nuclear Factor-κB Pathway
Jie Li, Jian-Jun Li, Jian-Guo He, Jing-long Nan, Yuan-lin Guo, Chang-ming Xiong

Erectile Dysfunction in High-Risk Hypertensive Patients Treated with Beta-Blockade Agents
Alberto Cordero, Vicente Bertomeu-Martínez, Pilar Mazón, Lorenzo Fácila, Vicente Bertomeu-González, et al

REVIEW: New Antithrombotics for Atrial Fibrillation
Luke R.E. Bereznicki, Gregory M. Peterson

Accepted Articles(accepted manuscripts)

Accepted Articles have been accepted for publication in CDR, but have not undergone the editing and proof-correction process. Accepted Articles are citable by DOI.

Early View(e-pub ahead of print)

CDR's Early View articles are definitive in format and presented in advance of print publication.

New Editors-in-Chief:

Henry Krum, PhD

Chim C. Lang, MD

We would like to thank former Editor Jane E. Freedman, MD, for her support over the past three years.

Cardiac Cell Therapies: The Next Generation (Review Article)
Yeong-Hoon Choi, Tomo Saric, Boris Nasseri, Stefan Hühn, Sophie Van Linthout, Roland Hetzer, et al

The Potential for Clinical Use of Cannabinoids in Treatment of Cardiovascular Diseases (Review Article)
Ronen Durst, Chaim Lotan

Hypertension, Dietary Salt Intake, and the Role of the Thiazide-Sensitive Sodium Chloride Transporter NCCT (Review Article)
Mark Glover, Annie Mercier Zuber, Kevin M. O'Shaughnessy

Aliskiren in the Treatment of Hypertension and Organ Damage (Review Article)
Graziano Riccioni

The Genetics of Blood Pressure and Hypertension: The Role of Rare Variation (Review Article)
Peter A. Doris

The Management of Acute Pulmonary Arterial Hypertension (Disease Focus Article)
Gan Hui-li

EXPEDITED is the new priority publication service from Cardiovascular Therapeutics exclusively for well conducted, well reported clinical trials.

• Priority peer review: 7 working days from online submission.
• Priority proofs: 7 working days from 'accept' decision.
• Priority online: 7 working days from proof approval to Early View publication.
• Priority print: 'Late Breaker' publication in the next print issue.

Click here for more information.